StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report sent to investors on Thursday. The brokerage issued a hold rating on the stock.

Other analysts have also recently issued reports about the company. Lake Street Capital lowered their target price on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Ekso Bionics in a report on Tuesday, January 14th.

Ekso Bionics Stock Down 6.6 %

Ekso Bionics stock opened at $0.58 on Thursday. The firm has a market capitalization of $12.74 million, a P/E ratio of -0.89 and a beta of 1.47. The company has a 50-day simple moving average of $0.66 and a 200-day simple moving average of $0.92. Ekso Bionics has a one year low of $0.50 and a one year high of $2.35. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.14 and a current ratio of 2.81.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The firm had revenue of $4.13 million during the quarter, compared to analyst estimates of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same quarter in the previous year, the business posted ($0.24) EPS. As a group, equities analysts expect that Ekso Bionics will post -0.48 earnings per share for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.